Dr. June Choon Wai Yee
Dr June Choon Wai Yee completed her BPharm (Hons) at Universiti Sains Malaysia in 2006 and thereafter her PhD in 2012. She underwent training as a pharmacist at Sungai Buloh Hospital from 2006 to 2007. Dr Choon was actively involved in various researches in biopharmaceutics and bioequivalence studies for over 20 pharmaceutical companies. She sat on the Joint Ethics Committee of the School of Pharmaceutical Sciences, USM-Hospital Lam Wah Ee on human clinical studies from 2008 - 2012.
From 2007 to 2009, Dr Choon also served as Hon. Secretary and Hon. Treasurer for the Penang Chapter of the Malaysian Pharmaceutical Society (MPS). Dr Choon joined Monash as a Lecturer in December 2014. She was also appointed as the Chair of the Organizing Committee for the very successful annual Monash Health Economics Forum for two consecutive years in 2015 and 2016. The annual event is co-organised by the Pharmaceutical Services Division, Ministry of Health Malaysia and also the Pharmaceutical Association of Malaysia (PhAMA), with strong support from industrial partners. Under Dr Choon's leadership, the Forum has since progressed and established itself as one of the most anticipated events on the local pharmaceutical industry calendar. With her keen interest and passion in continuous education, Dr Choon has also completed her training in Health Economics with the Department of Economics and Related Studies, The University of York.
- Postgraduate Certificate in Health Economics (PgCert), Department of Economics and Related Studies, University of New York, 2018
- Doctor of Philosophy, University Sains Malaysia, 2010
- Bachelor of Science in Pharmacy (Hons), University Sains Malaysia, 2006
- Health Economics
Book chapter: Interpretation of Laboratory Data and General Physical Examination by Pharmacists by 6 authors: Seeba Zachariah, Kiran Kumar, Shaun Wen Huey Lee, Wai Yee Choon, Saba Naeem and Christine Leong (2018) in "Clinical Pharmacy Education, Practice and Research - Clinical Pharmacy, Drug Information, Pharmacovigilance, Pharmacoeconomics and Clinical Research" by Dixon Thomas in Elsevier, Netherlands, United Kingdom and United States
Scholarly Journals (Refereed Only)
June WY Choon, David BC Wu, HY Chong, William TL Lo, Catherine SY Chong, WS Chung, Eileena MC Chui, Brian Tomlinson, Vivian WY Lee, SC Lee & Kenneth KC Lee, (2018). Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong, Journal of Medical Economics, 2018 Dec 18:1. https://doi.org/10.1080/13696998.2018.1560749
Hor CP, Fung WY, Ang HA, Lim SC, Kam LY, Sim SW, Lim LH, Choon WY, Wong JW, Ch'ng ASH, Beh KKM, Wee HC, Ong LM, Khan NAK, Sulaiman SAS, Shuaib IL, Bakar 7, Yusof 8, Yusof YM, Abu Bakar F, Tang WS, Teh HL, Wahid NA, Saaidin S, Idris N, Yoon CK, Ong HN, Ganapathy JT, Loo CE3, Samy MM, Zainal H, Dharan SCS, Ooi BY, Teoh PY, Tye YL, Yeoh CA, Low DW, Looi, Yuen KH, (2018). Efficacy of Oral Mixed Tocotrienols in Diabetic Peripheral Neuropathy - a Randomized Clinical Trial, JAMA Neurology. https://doi.org/10.1001/jamaneurol.2017.4609
Ibrahim S, Yee JC, Gupta M, Murugiah MK, Ming LC, (2016). Safety and efficacy of health supplement for weight Loss, Arch Pharma Pract 2016;7:S11-5. DOI: 10.4103/2045-080X.183031
Ab Rahman WA, Lee KS, Yee JC, Gupta M, Ming LC (2016). Evidence of Garcinia cambogia as a fat burning and appetite suppressing agents, Arch Pharma Pract 2016;7:S22-8.
Nuri TH, Yee JC, Gupta M, Khan MA, Ming LC, (2016). A review of Panax ginseng as an herbal medicine, Arch Pharma Pract 2016;7:S61-5.
Ali SA, Manan MM, Hassali MA, Kassab YW, Choon WY and Masri MB, (2013). Use of Generic Medicines: Perspectives of consumers living in urban and suburban areas of Klang Valley in Malaysia, Journal of Medical Marketing, Vol 13, Issue 4, Nov 2013 pp. 242 – 250
Zaheer-Ud-Din Babar, PhD, Nur Rashidah Mohd Zaini, MRCPCH, Choon Wai Yee, BPharm, (2006). Harm Reduction Program and Methadone Poisoning: Implications for Pediatric Public Health in Malaysia, Journal of Pharmacy Practice 19;5:1-2, 2006
Conference Proceeding (refereed Only)
Real world evidence of improved healthcare utilization in patients with recent onset schizophrenia afterpaliperidone Palmitate once=monthly treatment in Hong Kong. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific, Tokyo, Japan, 2018.
Cost-effectiveness of Edoxaban in patients with non-valvular atrial fibrillation in Hong Kong. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific, Tokyo, Japan, 2018.
Choon JWY, Wu DBC, Lee KKC, (2017). A Preliminary Cost Analysis of Schizophrenic Patients Who Are Stabilized on 1-Monthly Long Acting Paliperidone Palmitate Injection Are Switched to the 3-Monthly Formulation in the Public Health Sector of Hong Kong. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, Glasglow 2017.
Wu DBC, Choon JWY, Lee KKC, (2017). Cost-Effectiveness of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in Hong Kong. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual
European Congress, Glasglow 2017.
Choon JWY, Wu DBC, Tomlinson B, Hu M, Chung WS, Lee SC, Lee VWY, Lee KKC, (2016). Outcomes Prediction Using a Generalized Linear Model in a Cohort of Schizophrenic Patients Receiving Paliperidone Long Acting Injectable Treatment in Hong Kong. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress, Vienna, Austria 2016.
Choon JWY, Wu DBC, Tomlinson B, Hu M, Chung WS, Lee SC, Lee VWY, Lee KKC, (2016). A Preliminary Analysis of Health Care Resource Utilization of Paliperidone Palmitate in the Treatment of Schizophrenia in the Public Health Care Sector of Hong Kong. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, Washington, DC USA. 2016
Antibiotic Prescription Practice For Severe Community-Acquired Pneumonia in the ICU, 10th Malaysian Thoracic
Other (Non-Refereed Publications Included)
Insight on Generic medicines and Bioequivalence, Pharmacy Practice, Pharmacy Today (MIMS Pharmacy), Oct 2015 issue
Research Grants (Co-Investigator)
Prof Kenneth Lee, Dr David Wu, Dr June Choon, (2016-2018). Cost effectiveness of Edoxaban in Patients with non-valvular atrial fibrillation and venous thromboembolism in Hong Kong, Daiichi Sankyo Hong Kong Ltd, HKD240,000.00
Prof Kenneth Lee, Dr David Wu, Dr June Choon, (2014-current). Health care utilization analysis of Paliperidone palmitate in the treatment of Schizophrenia in the public health care sector of Hong Kong, Janssen Pharmaceuticals (HK), HKD250,000.00
Prof Kenneth Lee, Dr David Wu, Dr June Choon, (2014-2017). The analysis and publication of Health Economics data for Dapagliflozin in Hong Kong, AstraZeneca Hong Kong Ltd, HKD260,000.00
Prof Kenneth Lee, Dr David Wu, Dr June Choon, (2016-2017). Proposal for study to assess budget impact of Secukinumab in psoriasis, psoriatic arthritis and anklylosing spondylitis in the public sector of Malaysia, Novartis Corp (Malaysia) Sdn Bhd, RM75,000.00
Prof Kenneth Lee, Dr David Wu, Dr June Choon, (2016-2017). Dapagliflozin budget impact analysis model and final budget impact analysis report, AstraZeneca Sdn Bhd, RM46,948.00
Prof Yuen Kah Hay, Dr June Choon, (2010-2015). Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus (VENUS), PEMANDU, RM3,000,000.00
Membership in Professional Bodies
Member, 2016 - Current
International Society For Pharmacoeconomics and Outcomes Research
Membership in Academic Editorial Committees
Reviewer, 2015- Current
Journal of Pharmaceutical Policy and Practice
Reviewer, Member, 2014 - Current
Value in Health (Regional Issues)
Reviewer, Member, 2013 - Current
International Journal of Marketing Studies